Reimagining the research approach to tuberculosis†

American Journal of Tropical Medicine and Hygiene

Volumn 98, Issue 3, 2018, Pages 650-652

  Fauci, Anthony S ^a   Eisinger, Robert W ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BCG VACCINE; ISONIAZID; RIFAPENTINE; VIRUS RNA;

ADAPTIVE IMMUNITY; COMBINATION CHEMOTHERAPY; COMORBIDITY; DIAGNOSTIC TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; INNATE IMMUNITY; LATENT TUBERCULOSIS; MEDICAL RESEARCH; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGENESIS; REVIEW; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; IMMUNOLOGY; MIXED INFECTION; PUBLIC HEALTH;

BIOMEDICAL RESEARCH; COINFECTION; HIV INFECTIONS; HUMANS; PUBLIC HEALTH; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 85043523450     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.17-0999     Document Type: Review

References (28)

1. Paulson T, 2013. Epidemiology: a mortal foe. Nature 502: S2-S3.
2. World Health Organization, 2017. Global Tuberculosis Report 2017. Geneva, Switzerland: WHO.
3. World Health Organization, 2017. Moscow Declaration to End TB. First WHO Ministerial Conference to Ending TB in the Sustainable Development Era: A Multisectoral Response, Moscow, Russia, November 16-17, 2017.
4. Fauci AS; NIAID Tuberculosis Working Group, 2008. Multidrug-resistant and extensively drug-resistant tuberculosis: the National Institute of Allergy and Infectious Diseases Research agenda and recommendations for priority research. J Infect Dis 197: 1493-1498.
5. Centers for Disease Control and Prevention, 1981. Kaposi’s sarcoma and pneumocystis pneumonia among homosexual men-New York City and California. MMWR Morb Mortal Wkly Rep 30: 305-308.
6. Centers for Disease Control and Prevention, 1981. Pneumocystis pneumonia-Los Angeles. MMWR Morb Mortal Wkly Rep 30: 250-252.
7. Palmer S et al., 2003. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 41: 4531-4536.
8. Marcus JL, Chao CR, Leyden WA, Xu L, Quesenberry CP Jr, Klein DB, Towner WJ, Horberg MA, Silverberg MJ, 2016. Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care. J Acquir Immune Defic Syndr 73: 39-46.
9. Centers for Disease Control and Prevention, 2016. Pre-Exposure Prophylaxis. Available at: https://www.cdc.gov/hiv/risk/prep/index.html. Accessed December 2, 2017.
10. Fauci AS, 2017. An HIV vaccine is essential for ending the HIV/ AIDS pandemic. JAMA 318: 1535-1536.
11. National Institute of Allergy and Infectious Diseases, 2016. First New HIV Vaccine Efficacy Study in Seven Years Has Begun. Bethesda, MD: NIAID.
12. National Institute of Allergy and Infectious Diseases, 2017. NIH and Partners Launch HIV Vaccine Efficacy Study. Bethesda, MD: NIAID.
13. U.S. Agency for International Development, 2015. United States Government Global Tuberculosis Strategy 2015-2019. Washington, DC: USAID.
14. World Health Organization, 2015. The End TB Strategy-Global Strategy and Targets for Tuberculosis Prevention, Care, and Control after 2015. Geneva, Switzerland: WHO.
15. Flynn JL, Chan J, 2001. Tuberculosis: latency and reactivation. Infect Immun 69: 4195-4201.
16. Pawlowski A, Jansson M, Skold M, Rottenberg ME, Kallenius G, 2012. Tuberculosis and HIV co-infection. PLoS Pathog 8: e1002464.
17. Mendez-Samperio P, 2017. Diagnosis of tuberculosis in HIV coinfected individuals: current status, challenges and opportunities for the future. Scand J Immunol 86: 76-82.
18. Venturini E, Turkova A, Chiappini E, Galli L, de Martino M, Thorne C, 2014. Tuberculosis and HIV co-infection in children. BMC Infect Dis 14 (Suppl 1): S5.
19. The Broad Institute, 2017. TB-ARC Project (Tuberculosis Antibiotic Resistance Catalog Project). Available at: https://www.broadinstitute.org/genome-sequencing-and-analysis/tbarc-project-tuberculosis-antibiotic-resistance-catalog-project. Accessed December 4, 2017.
20. World Health Organization, 2017. Antibacterial Agents in Clinical Development-An Analysis of the Antibacterial Clinical Development Pipeline, Including Tuberculosis. Geneva, Switzerland: WHO.
21. Stop TB, Partnership, 2017. 2017 Global New TB Drug Pipeline. Available at: http://www.newtbdrugs.org/pipeline/clinical. Accessed December 2, 2017.
22. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents, 2017. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Available at: https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/325/tb. Accessed December 5, 2017.
23. International Federation of Pharmaceutical Manufacturers, 2017. TB Drug Accelerator Program. Available at: http://partnerships.ifpma.org/partnership/tb-drug-accelerator-program. Accessed December 2, 2017.
24. Sizemore CF, Hafner R, Fauci AS, 2017. NIH Statement on World Tuberculosis Day. Bethesda, MD: NIAID.
25. Stop TB Partnership Working Group on New TB Vaccines, 2017. TB Vaccine Pipeline. Available at: http://www.newtbvaccines.org/tb-vaccine-pipeline/. Accessed December 5, 2017.
26. World Health Organization, 2016/2017. Global Investments in Tuberculosis Research and Development: Past, Present, and Future. Geneva, Switzerland: WHO.
27. Centers for Disease Control and Prevention, 2016. BCG Vaccine. Available at: https://www.cdc.gov/tb/publications/factsheets/prevention/bcg.htm. Accessed December 4, 2017.
28. Brennan MJ, Thole J, 2012. Tuberculosis vaccines: a strategic blueprint for the next decade. Tuberculosis (Edinb) 92 (Suppl 1): S6-S13.